Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateGlobeNewsWire • 05/06/26
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and AustraliaGlobeNewsWire • 04/21/26
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026GlobeNewsWire • 04/20/26
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common StockGlobeNewsWire • 04/16/26
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune DiseasesGlobeNewsWire • 04/15/26
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common StockGlobeNewsWire • 04/13/26
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma TranscriptSeeking Alpha • 04/13/26
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCLSeeking Alpha • 04/13/26
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaBusiness Wire • 04/13/26
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCLGlobeNewsWire • 04/13/26
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026GlobeNewsWire • 04/10/26
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdateGlobeNewsWire • 03/12/26
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in FocusZacks Investment Research • 03/09/26
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business UpdateGlobeNewsWire • 03/02/26
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit TranscriptSeeking Alpha • 02/18/26
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?Zacks Investment Research • 02/11/26
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR TGlobeNewsWire • 01/08/26
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisGlobeNewsWire • 12/15/25
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR TSeeking Alpha • 11/07/25